Pfizer’s Amplyx Buy Continues Infectious Disease Deal-Making Spree

 
• By Joseph Haas

Pfizer will develop the novel antifungal fosmanogepix. The big pharma has made several other recent anti-infective deals, including when it expanded its BioNTech vaccine alliance to include COVID-19.

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.
Pfizer makes its second major deal in the antifungal space in four years

More from Deals

More from Business